All In Biotech

Drug Trial Radar · NCT05540327

The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)

A Phase II, Double-blind, Dose-Ranging, Parallel, Long-term Extension Study to Evaluate the Safety and Efficacy of Enpatoran in Participants With Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus and/or Systemic Lupus Erythematosus Having Completed the WILLOW (MS200569_0003) Study Treatment (WILLOW LTE)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 381 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

381

Actual

Start

Sep 16, 2022

Primary completion

Aug 12, 2028

Study completion Aug 12, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 76 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the long term safety and efficacy of orally administered M5049 in participants with subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and/or systemic lupus erythematosus (SLE) who have completed the 24 week treatment period of Willow study (MS200569\_0003 \[NCT05162586\]).

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • M5049 low doseDrug

    Participants will receive film-coated tablets of M5049 at a low dose orally, twice a day (BID) for up to 194 weeks.

  • M5049 medium doseDrug

    Participants will receive film-coated tablets of M5049 at a medium dose orally, BID for up to 194 weeks.

  • M5049 high doseDrug

    Participants will receive film-coated tablets of M5049 at a high dose orally, BID for up to 194 weeks.

  • PlaceboDrug

    Participants will receive M5049 matching placebo orally, BID for up to 194 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs)Time frame: Baseline up to Week 50 (Long Term Extension Part 1)
  2. Part 2: Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Event of Special Interest (AESIs)Time frame: Baseline up to Week 194 (LTE Part 1 and LTE Prolongation Part 2))

Locations

122 sites in 22 countries. Site status is shown where the registry gives one.

  • The Lundquist Institute at Harbor-UCLA Medical Center

    Torrance, California

  • Bay Area Arthritis and Osteoporosis

    Brandon, Florida

  • Advance Medical Research Center

    Miami, Florida

  • Dawes Fretzin Dermatology Group, LLC

    Indianapolis, Indiana

  • AA MRC LLC Ahmed Arif Medical Research Center

    Grand Blanc, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Ohio State University - CTMO Parent

    Columbus, Ohio

  • Ramesh C Gupta, MD

    Memphis, Tennessee

  • Centro de Investigaciones Medicas Mar del Plata - CIM

    Buenos Aires, Argentina

  • CINME - Centro De Investigaciones Metabolicas

    Buenos Aires, Argentina

  • Buenos Aires Skin

    Ciudad Autonoma Buenos Aires, Argentina

  • Hospital Militar Central Dr. Cosme Argerich

    Ciudad Autonoma Buenos Aires, Argentina

  • Centro de Investigaciones Medicas Mar del Plata - CIM

    Mar del Plata, Argentina

  • Instituto de Reumatologia

    Mendoza, Argentina

  • Instituto Medico de alta Complejidad San Isidro S.A (IMAC)

    San Fernando, Argentina

  • CER San Juan Centro Polivalente de Asistencia e Inv. Clinica

    San Juan, Argentina

  • Centro Dermatologico Schejtman

    San Miguel, Argentina

  • PSORIAHUE-Medicina Interdisciplinar

    San Miguel, Argentina

  • Centro de Investigaciones Medicas Tucuman

    San Miguel de Tucumán, Argentina

  • Investigaciones Clinicas Tucuman

    San Miguel de Tucumán, Argentina

  • Monash Medical Centre Clayton

    Clayton, Australia

  • Veracity Clinical Research

    Woolloongabba, Australia

  • Santa Casa de Misericórdia de Belo Horizonte

    Belo Horizonte, Brazil

  • Oncovida - Centro de Onco-Hematologia de Mato Grosso

    Cuiabá, Brazil

  • Clínica SER da Bahia

    Graça, Brazil

  • CMiP - Centro Mineiro de Pesquisa

    Juiz de Fora, Brazil

  • Hospital Moinhos de Vento

    Moinhos de Vento, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto - CIP - Centro Integrado de Pesquisa

    São José, Brazil

  • CEPIC - Centro Paulista de Investigação Clínica e Serviços Médicos

    São Paulo, Brazil

  • DCC 'Sveti Georgi' EOOD - Cardiology Office

    Haskovo, Bulgaria

  • MC Artmed OOD

    Plovdiv, Bulgaria

  • DCC 1 Sevlievo EOOD

    Sevlievo, Bulgaria

  • DCC Focus 5 - MEOH OOD

    Sofia, Bulgaria

  • Military Medical Academy - MHAT - Sofia

    Sofia, Bulgaria

  • UMHAT "Sv. Ivan Rilski", EAD - Clinic of Rheumatology

    Sofia, Bulgaria

  • UMHAT "Sv. Ivan Rilski", EAD - Clinica of Rheumatology

    Sofia, Bulgaria

  • Clinica Alemana de Osorno - Corporacion de Beneficencia Osorno

    Los Lagos, Chile

  • BioMedica Research Group - Psicomedica Clinical and Research Group

    Santiago, Chile

  • CeCim Biocinetic

    Santiago, Chile

  • Centro Medico Prosalud

    Santiago, Chile

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.